Volume 90 Issue 37 | p. 17 | Concentrates
Issue Date: September 10, 2012

Janssen Licenses Genmab Cancer Drug

Department: Business
Keywords: pharmaceuticals, oncology, cancer, monoclonal antibodies

Janssen Biotech, an arm of Johnson & Johnson, will pay Genmab $55 million up front for access to the monoclonal antibody daratumumab and a backup antibody. As part of the deal, J&J will invest roughly $80 million in the Danish biotech company. Janssen will also take on development costs for daratumumab, including paying for ongoing Phase I/II clinical trials in patients with multiple myeloma. Daratumumab binds to CD38, a protein on the surface of several kinds of immune cells.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment